319 results
Page 3 of 16
8-K
EX-99.1
10j8aw
4 Aug 22
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
7:01am
8-K
EX-99.1
4m04m12itip65h5
10 May 22
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
4:01pm
8-K/A
EX-99.1
bu8rqpdzscc90 9od19
9 May 22
Amicus Therapeutics Announces First Quarter 2022 Financial Results
12:54pm
8-K
EX-99.1
j4mp2bp13hjd1
9 May 22
Amicus Therapeutics Announces First Quarter 2022 Financial Results
7:00am
8-K
EX-99.2
uo4orrc
9 May 22
Amicus Therapeutics Announces First Quarter 2022 Financial Results
7:00am
8-K
EX-99.2
t052qfferweemc mx1
24 Feb 22
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
7:00am
8-K
EX-99.1
gz2i7a g338xk
24 Feb 22
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
7:00am
8-K
EX-99.2
pc8isgqsass7jpkvqdx
10 Jan 22
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
7:00am
8-K
EX-99.1
nw74o
10 Jan 22
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
7:00am
8-K
EX-99.1
do52i1k6e4g ivs5uq20
3 Dec 21
Other Events
7:00am
8-K
nl8fvq0bd
18 Nov 21
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
7:01am
8-K
EX-99.1
s01 7p480
18 Nov 21
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
7:01am
8-K
EX-99.1
1ob484stfd d80p3h3
9 Nov 21
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
7:07am
8-K
EX-99.2
3om5ucc9u pbpcwbo7lk
9 Nov 21
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
7:07am
DEFA14A
m13n0l3mv0zjs3m
29 Sep 21
Additional proxy soliciting materials
12:27pm
8-K
EX-10.5
a8t9l z6mpnbx135y5nw
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am